Investors Purchase Large Volume of Call Options on BioNTech (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) saw unusually large options trading activity on Monday. Stock traders bought 1,989 call options on the company. This represents an increase of 31% compared to the average daily volume of 1,519 call options.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares in the last quarter. CWM LLC raised its holdings in BioNTech by 657.6% in the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares during the period. Frazier Financial Advisors LLC acquired a new position in BioNTech in the 4th quarter worth about $30,000. Covestor Ltd purchased a new position in shares of BioNTech during the 3rd quarter valued at approximately $32,000. Finally, First Horizon Advisors Inc. acquired a new stake in BioNTech in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 2.6 %

BioNTech stock opened at $90.88 on Wednesday. BioNTech has a 52 week low of $85.21 and a 52 week high of $125.83. The firm has a market cap of $21.60 billion, a price-to-earnings ratio of 22.06 and a beta of 0.25. The business’s 50-day moving average price is $90.53 and its 200 day moving average price is $95.99. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. As a group, sell-side analysts anticipate that BioNTech will post -1.74 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on BNTX. HC Wainwright restated a “buy” rating and set a $107.00 price target on shares of BioNTech in a research note on Wednesday, April 17th. BMO Capital Markets cut their target price on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday. TD Cowen lifted their price target on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research report on Tuesday. Canaccord Genuity Group reiterated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. Finally, The Goldman Sachs Group reduced their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $118.27.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.